Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000627 · ClinicalTrials.gov registry record · NA
Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome
A NA study of HIV Infections and Histoplasmosis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 20
- Study locations
NCT00000627: Completed NA study of HIV Infections and Histoplasmosis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00000627 is a NA study of HIV Infections and Histoplasmosis that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 90 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000627, a NA study of HIV Infections and Histoplasmosis, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the use of fluconazole as (1) induction therapy in histoplasmosis, (2) maintenance therapy to prevent relapse of histoplasmosis. Histoplasmosis is a serious opportunistic infection in patients with AIDS. Fluconazole is a triazole antifungal agent that has been used successfully in the treatment of experimental histoplasmosis in animals, but has not been completely evaluated in patients for this use. It has been approved by the Food and Drug Administration for certain other fungal infections. Nevertheless, physicians are prescribing it to their patients with histoplasmosis. This is a pilot study to examine the role of fluconazole for treating histoplasmosis in AIDS patients.
Conditions Studied
Interventions
- DRUG Fluconazole
Study Locations (20)
New York
- Beth Israel Med Ctr - New York
- Cornell Univ Med Ctr - New York
- Saint Luke's - Roosevelt Hosp Ctr - New York
- Mount Sinai Med Ctr - New York
- Montefiore Drug Treatment Ctr / Bronx Municipal Hosp - The Bronx
- Montefiore Family Health Ctr / Bronx Municipal Hosp - The Bronx
- Samaritan Village Inc / Bronx Municipal Hosp - The Bronx
- Montefiore Med Ctr / Bronx Municipal Hosp - The Bronx
- North Central Bronx Hosp / Bronx Municipal Hosp - The Bronx
Missouri
- Univ of Missouri at Kansas City School of Medicine - Kansas City
- Infectious Diseases Association / Research Med Ctr - Kansas City
- St Louis Regional Hosp / St Louis Regional Med Ctr - St Louis
California
- Univ of Southern California / LA County USC Med Ctr - Los Angeles
- San Francisco Veterans Administration Med Ctr - San Francisco
Indiana
- Indiana Univ Hosp - Indianapolis
- Methodist Hosp of Indiana / Life Care Clinic - Indianapolis
Massachusetts
- Baystate Med Ctr of Springfield - Springfield
- Worcester Memorial Hosp / Med Ctr of Cntrl MA-Memorial - Worcester
Alabama
- Univ of Alabama at Birmingham - Birmingham
Ohio
- Ohio State Univ Hosp Clinic - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Est. Completion | 1994-11 |
| Phase | NA |
What the finished NCT00000627 record still lists
NCT00000627 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Fluconazole is the first listed.
NCT00000627 names 20 study sites across 7 states, led by New York, Missouri, California.
Frequently Asked Questions
What is clinical trial NCT00000627 about?
NCT00000627 is a clinical study titled "Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome". To evaluate the use of fluconazole as (1) induction therapy in histoplasmosis, (2) maintenance therapy to prevent relapse of histoplasmosis. Histoplasmosis is a serious opportunistic infection in patients with AIDS. Fluconazole is a triazole antifungal agent that has been used successfully in the t...
What is the current status of trial NCT00000627?
This trial is currently completed. It is a NA study. The enrollment target is 90 participants. Estimated completion is 1994-11.
What conditions does trial NCT00000627 study?
This clinical trial studies the following conditions: HIV Infections, Histoplasmosis.
What interventions are being tested in trial NCT00000627?
The interventions under investigation include: Fluconazole (DRUG).
Who is sponsoring clinical trial NCT00000627?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000627 being conducted?
This trial has 20 study locations across Alabama, California, Indiana, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00000627's enrollment target sits among peer trials
90 287th of 542 higher than 251 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery